

June 18, 2020

## **RaQualia Additionally Licensed Tegoprazan to HK inno.N for Non-licensed Countries and Regions except Japan**

RaQualia announced today that the Company has additionally licensed tegoprazan (RQ-00000004/CJ-12420/K-CAB<sup>®</sup>, hereinafter called “tegoprazan”), a drug for gastroesophageal reflux disease, to HK inno.N Corporation (Joint representative directors: Seok-Hee Kang and Sang-Hyun Yoon, headquartered in Seoul, Korea; hereinafter called “HK inno.N”) for all non-licensed countries and regions including emerging and developing countries except Japan.

RaQualia is eligible to receive a certain share of the license income earned by HK inno.N as well as royalties on the sale of tegoprazan. There is no upfront payment due to this matter.

RaQualia and HK inno.N will continue to work together to maximize the value of tegoprazan, expanding the treatment options for gastrointestinal diseases, and will strive to further contribute to improving patients’ QOL (Quality of Life).